| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
|
N Engl J Med
|
2006
|
18.25
|
|
2
|
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.
|
N Engl J Med
|
2008
|
11.61
|
|
3
|
Feasibility of treating prehypertension with an angiotensin-receptor blocker.
|
N Engl J Med
|
2006
|
9.40
|
|
4
|
Critical issues in peripheral arterial disease detection and management: a call to action.
|
Arch Intern Med
|
2003
|
4.72
|
|
5
|
Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial.
|
JAMA
|
2003
|
3.71
|
|
6
|
Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.
|
Lancet
|
2010
|
3.16
|
|
7
|
ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension.
|
J Am Coll Cardiol
|
2011
|
2.83
|
|
8
|
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial.
|
J Am Coll Cardiol
|
2007
|
2.56
|
|
9
|
Changes in albuminuria predict mortality and morbidity in patients with vascular disease.
|
J Am Soc Nephrol
|
2011
|
2.40
|
|
10
|
Expanding the definition and classification of hypertension.
|
J Clin Hypertens (Greenwich)
|
2005
|
2.35
|
|
11
|
Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension.
|
Hypertension
|
2003
|
2.06
|
|
12
|
Assessment of drug-induced increases in blood pressure during drug development: report from the Cardiac Safety Research Consortium.
|
Am Heart J
|
2013
|
2.05
|
|
13
|
ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents.
|
Circulation
|
2011
|
1.97
|
|
14
|
Blood pressure measurement reliability among different racial-ethnic groups in a stroke prevention study.
|
Blood Press Monit
|
2014
|
1.97
|
|
15
|
The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy.
|
Hypertension
|
2006
|
1.71
|
|
16
|
Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.
|
Hypertension
|
2011
|
1.69
|
|
17
|
Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide.
|
Am J Hypertens
|
2004
|
1.60
|
|
18
|
Prediction of cardiovascular outcome by estimated glomerular filtration rate and estimated creatinine clearance in the high-risk hypertension population of the VALUE trial.
|
J Hypertens
|
2007
|
1.59
|
|
19
|
Renal outcomes in hypertensive Black patients at high cardiovascular risk.
|
Kidney Int
|
2011
|
1.51
|
|
20
|
Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study.
|
J Clin Hypertens (Greenwich)
|
2007
|
1.50
|
|
21
|
Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in older vs younger patients with hypertension uncontrolled with monotherapy.
|
Am J Geriatr Cardiol
|
2008
|
1.48
|
|
22
|
Effect of combining extended-release carvedilol and lisinopril in hypertension: results of the COSMOS study.
|
J Clin Hypertens (Greenwich)
|
2010
|
1.46
|
|
23
|
Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring.
|
J Clin Hypertens (Greenwich)
|
2011
|
1.44
|
|
24
|
The management of trauma venous injury: civilian and wartime experiences.
|
Perspect Vasc Surg Endovasc Ther
|
2006
|
1.40
|
|
25
|
Combination therapy in hypertension.
|
J Am Soc Hypertens
|
2010
|
1.28
|
|
26
|
Adherence and persistence with taking medication to control high blood pressure.
|
J Am Soc Hypertens
|
2011
|
1.20
|
|
27
|
Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension.
|
Hypertension
|
2012
|
1.14
|
|
28
|
ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension.
|
J Am Soc Hypertens
|
2011
|
1.09
|
|
29
|
Turning attention to the young.
|
J Clin Hypertens (Greenwich)
|
2011
|
1.07
|
|
30
|
Predictors of in-hospital mortality in 1333 patients with acute myocardial infarction complicated by cardiogenic shock treated with primary percutaneous coronary intervention (PCI); Results of the primary PCI registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte (ALKK).
|
Eur Heart J
|
2004
|
1.06
|
|
31
|
International expert consensus statement: Percutaneous transluminal renal denervation for the treatment of resistant hypertension.
|
J Am Coll Cardiol
|
2013
|
1.05
|
|
32
|
When and how to use self (home) and ambulatory blood pressure monitoring.
|
J Am Soc Hypertens
|
2010
|
1.04
|
|
33
|
ASH Position Paper: Dietary approaches to lower blood pressure.
|
J Clin Hypertens (Greenwich)
|
2009
|
1.03
|
|
34
|
The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial.
|
J Clin Hypertens (Greenwich)
|
2005
|
1.02
|
|
35
|
Mortality and morbidity in relation to changes in albuminuria, glucose status and systolic blood pressure: an analysis of the ONTARGET and TRANSCEND studies.
|
Diabetologia
|
2014
|
0.98
|
|
36
|
Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial.
|
J Hypertens
|
2006
|
0.96
|
|
37
|
Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study.
|
J Clin Hypertens (Greenwich)
|
2012
|
0.95
|
|
38
|
Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension.
|
Am J Hypertens
|
2004
|
0.95
|
|
39
|
Efficacy of combination therapy for systolic blood pressure in patients with severe systolic hypertension: the Systolic Evaluation of Lotrel Efficacy and Comparative Therapies (SELECT) study.
|
J Clin Hypertens (Greenwich)
|
2005
|
0.95
|
|
40
|
Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes.
|
J Clin Hypertens (Greenwich)
|
2006
|
0.94
|
|
41
|
Angiotensin-converting enzyme inhibitors and angioedema: estimating the risk.
|
Hypertension
|
2008
|
0.92
|
|
42
|
ASH position paper: dietary approaches to lower blood pressure.
|
J Am Soc Hypertens
|
2010
|
0.92
|
|
43
|
Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension.
|
Am J Cardiol
|
2011
|
0.91
|
|
44
|
Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil.
|
Am J Med
|
2012
|
0.91
|
|
45
|
Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting.
|
Am Heart J
|
2006
|
0.90
|
|
46
|
Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery disease.
|
Am J Cardiol
|
2013
|
0.87
|
|
47
|
Academic physicians confront a hostile world: the creation of ACRE.
|
J Clin Hypertens (Greenwich)
|
2009
|
0.87
|
|
48
|
Irbesartan/HCTZ fixed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapy.
|
J Natl Med Assoc
|
2006
|
0.87
|
|
49
|
A U.S. Army Forward Surgical Team's experience in Operation Iraqi Freedom.
|
J Trauma
|
2004
|
0.86
|
|
50
|
A randomized, double-blind, placebo-controlled parallel-group study to assess the efficacy and safety of nebivolol, a novel beta-blocker, in patients with mild to moderate hypertension.
|
J Clin Hypertens (Greenwich)
|
2007
|
0.86
|
|
51
|
Ambulatory blood pressure monitoring in the primary care setting: assessment of therapy on the circadian variation of blood pressure from the MICCAT-2 Trial.
|
Blood Press Monit
|
2005
|
0.85
|
|
52
|
Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial).
|
Am J Cardiol
|
2009
|
0.85
|
|
53
|
Outcome after out-of-hospital cardiac arrest in a physician-staffed emergency medical system according to the Utstein style.
|
Am Heart J
|
2007
|
0.84
|
|
54
|
Effect of antihypertensive monotherapy and combination therapy on arterial distensibility and left ventricular mass.
|
Am J Hypertens
|
2004
|
0.83
|
|
55
|
Use of an olmesartan medoxomil-based treatment algorithm for hypertension control.
|
J Clin Hypertens (Greenwich)
|
2004
|
0.83
|
|
56
|
Defining the antihypertensive properties of the angiotensin receptor blocker telmisartan by a practice-based clinical trial.
|
Am J Hypertens
|
2003
|
0.82
|
|
57
|
A focus on heart failure and other age-related cardiovascular conditions.
|
Am J Geriatr Cardiol
|
2005
|
0.81
|
|
58
|
Efficacy and duration of benazepril plus amlodipine or hydrochlorothiazide on 24-hour ambulatory systolic blood pressure control.
|
Hypertension
|
2010
|
0.81
|
|
59
|
Comparative antihypertensive efficacy of angiotensin receptor blocker-based treatment in African-American and white patients.
|
J Clin Hypertens (Greenwich)
|
2005
|
0.80
|
|
60
|
Results of the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) trial by geographical region.
|
J Hypertens
|
2005
|
0.80
|
|
61
|
How well do we care for patients with hypertension?
|
J Clin Hypertens (Greenwich)
|
2012
|
0.80
|
|
62
|
Treatment of hypertension in patients with diabetes--an update.
|
J Am Soc Hypertens
|
2010
|
0.80
|
|
63
|
Hypertension, the metabolic syndrome, and the risk of developing diabetes: is it time to change the guidelines?
|
J Clin Hypertens (Greenwich)
|
2004
|
0.79
|
|
64
|
Angiotensin-receptor blockade, cancer, and concerns.
|
Lancet Oncol
|
2010
|
0.78
|
|
65
|
24-hour ambulatory blood pressure in the ACCOMPLISH trial.
|
N Engl J Med
|
2010
|
0.78
|
|
66
|
High Blood Pressure 2016: Why Prevention and Control Are Urgent and Important. The World Hypertension League, International Society of Hypertension, World Stroke Organization, International Diabetes Foundation, International Council of Cardiovascular Prevention and Rehabilitation, International Society of Nephrology.
|
J Clin Hypertens (Greenwich)
|
2016
|
0.78
|
|
67
|
Long-term cardiovascular consequences of diuretics vs calcium channel blockers vs angiotensin-converting enzyme inhibitors.
|
JAMA
|
2003
|
0.78
|
|
68
|
Drug choice affects treatment compliance and blood pressure outcomes in elderly hypertensive patients.
|
Am J Geriatr Cardiol
|
2007
|
0.77
|
|
69
|
The foundation role of beta blockers across the cardiovascular disease spectrum: a year 2009 update.
|
Am J Med
|
2010
|
0.77
|
|
70
|
Delayed evaluation of combat-related penetrating neck trauma.
|
J Vasc Surg
|
2006
|
0.77
|
|
71
|
Physician (investigator) inertia in apparent treatment-resistant hypertension - insights from large randomized clinical trials. Lennart Hansson Memorial Lecture.
|
Blood Press
|
2014
|
0.76
|
|
72
|
Who should be treated with implantable cardioverter-defibrillators?
|
Am J Geriatr Cardiol
|
2006
|
0.76
|
|
73
|
A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
|
Am Heart J
|
2005
|
0.76
|
|
74
|
Clinical experience with perindopril in elderly hypertensive patients: a subgroup analysis of a large community trial.
|
Am J Cardiovasc Drugs
|
2004
|
0.76
|
|
75
|
Amlodipine+benazepril is superior to hydrochlorothiazide+benazepril irrespective of baseline pulse pressure: subanalysis of the ACCOMPLISH trial.
|
J Clin Hypertens (Greenwich)
|
2014
|
0.76
|
|
76
|
ALLHAT--all hit or all miss? Key questions still remain.
|
Am J Cardiol
|
2003
|
0.76
|
|
77
|
Expanding the scope of hypertension: are we creating new diseases?
|
J Clin Hypertens (Greenwich)
|
2006
|
0.76
|
|
78
|
Beta-blocker therapy in hypertension: a need to pause and reflect.
|
J Am Coll Cardiol
|
2008
|
0.75
|
|
79
|
Putting LIFE into hypertension.
|
Curr Hypertens Rep
|
2002
|
0.75
|
|
80
|
Management of heart failure in the elderly: still much to be learned.
|
Am J Geriatr Cardiol
|
2002
|
0.75
|
|
81
|
Common cardiac conditions in the elderly are still not well understood.
|
Am J Geriatr Cardiol
|
2004
|
0.75
|
|
82
|
Hypertension: BP reduction in patients with diabetes--uncertainties remain.
|
Nat Rev Cardiol
|
2010
|
0.75
|
|
83
|
Coronary risk attributes, coronary risk reduction, and clinical outcomes.
|
Am J Geriatr Cardiol
|
2006
|
0.75
|
|
84
|
Patient selection, statistical presumption, and uncertainty of outcomes.
|
Am J Geriatr Cardiol
|
2007
|
0.75
|
|
85
|
In response: the ethics and value of professional medical writing assistance.
|
Endocr Pract
|
2013
|
0.75
|
|
86
|
The elderly and cardiovascular disease: some differences, but many similarities to their younger counterparts.
|
Am J Geriatr Cardiol
|
2004
|
0.75
|
|
87
|
Management of Junctional Hemorrhage in Tactical Combat Casualty Care: TCCC Guidelines?Proposed Change 13-03.
|
J Spec Oper Med
|
2013
|
0.75
|
|
88
|
Progress in treating hypertension.
|
Am J Geriatr Cardiol
|
2008
|
0.75
|
|
89
|
Obesity, blood pressure, and cardiovascular outcomes - Authors' reply.
|
Lancet
|
2013
|
0.75
|
|
90
|
Denial of standard treatment to the elderly: why?
|
Am J Geriatr Cardiol
|
2007
|
0.75
|
|
91
|
Design of the Omapatrilat in Persons with Enhanced Risk of Atherosclerotic events (OPERA) trial.
|
Am J Hypertens
|
2002
|
0.75
|
|
92
|
Atrial fibrillation: many therapeutic options, but great uncertainty about optimal treatment.
|
Am J Geriatr Cardiol
|
2002
|
0.75
|
|
93
|
Effects of treatment for hypertension on cognitive function in the elderly.
|
Curr Hypertens Rep
|
2006
|
0.75
|
|
94
|
The metabolic syndrome--what is it and how should it be managed?
|
J Clin Hypertens (Greenwich)
|
2006
|
0.75
|
|
95
|
New frontiers in cardiovascular aging.
|
Am J Geriatr Cardiol
|
2003
|
0.75
|
|
96
|
Hippocrates, Maimonides, and End-of-Life Issues.
|
Am J Geriatr Cardiol
|
2004
|
0.75
|
|
97
|
The potential role of nitric oxide in cardiovascular safety when treating patients with osteoarthritis and hypertension: a moderated panel discussion.
|
Am J Med
|
2009
|
0.75
|
|
98
|
The evolution of combination therapy in treating hypertension.
|
J Clin Hypertens (Greenwich)
|
2007
|
0.75
|
|
99
|
Data-driven clinical care.
|
Am J Geriatr Cardiol
|
2002
|
0.75
|
|
100
|
Only a patent right external carotid and left vertebral artery in a neurologically asymptomatic patient.
|
J Vasc Surg
|
2011
|
0.75
|
|
101
|
Efficacy of combination therapy with amlodipine besylate/benazepril hydrochloride for lowering systolic blood pressure in stage 2 hypertension.
|
Am J Geriatr Cardiol
|
2006
|
0.75
|
|
102
|
Yet more hypertension guidelines: what do they add?
|
J Hypertens
|
2003
|
0.75
|
|
103
|
Guidelines of the Cardiogeriatrics Department of the Brazilian Cardiology Society: commentary by Editorial Board Members of The American Journal of Geriatric Cardiology.
|
Am J Geriatr Cardiol
|
2004
|
0.75
|
|
104
|
The antihypertensive efficacy and safety of a chronotherapeutic formulation of propranolol in patients with hypertension.
|
J Clin Hypertens (Greenwich)
|
2004
|
0.75
|
|
105
|
Management of secondary hemorrhage from early graft failure in military extremity wounds.
|
J Trauma Acute Care Surg
|
2012
|
0.75
|
|
106
|
Medicare drug therapy in the elderly: pharmacotherapy, politics, and economics at the crossroads.
|
Am J Geriatr Cardiol
|
2005
|
0.75
|
|
107
|
Drug therapy in the elderly.
|
Am J Geriatr Cardiol
|
2003
|
0.75
|
|
108
|
Hypertension at elderly age: what we know and what we must learn.
|
Am J Geriatr Cardiol
|
2002
|
0.75
|
|
109
|
Hypertension guidelines: a major reappraisal critically examines the available evidence.
|
J Clin Hypertens (Greenwich)
|
2010
|
0.75
|
|
110
|
Appropriate dose transition to a controlled-release formulation of carvedilol in patients with hypertension.
|
Rev Cardiovasc Med
|
2008
|
0.75
|
|
111
|
Is there more to life than blood pressure?
|
J Clin Hypertens (Greenwich)
|
2005
|
0.75
|
|
112
|
Endovascular repair of an abdominal aortic aneurysm in a patient with stenosis of bilateral common iliac artery stents.
|
Ann Vasc Surg
|
2011
|
0.75
|
|
113
|
Second Consensus on Treatment of Patients Recently Diagnosed With Mild Hypertension and Low Cardiovascular Risk.
|
Curr Probl Cardiol
|
2020
|
0.75
|
|
114
|
ONTARGET: questions asked, questions answered.
|
J Clin Hypertens (Greenwich)
|
2008
|
0.75
|
|
115
|
Introduction. The cardiovascular continuum in the 21st century: renin-angiotensin system blockade, the cardiovascular continuum in the 21st century.
|
Am J Cardiol
|
2010
|
0.75
|
|
116
|
The Cardiovascular Health Study: a national treasure of cardiovascular information about the elderly.
|
Am J Geriatr Cardiol
|
2004
|
0.75
|
|
117
|
A dramatic addition to the Journal of Clinical Hypertension.
|
J Clin Hypertens (Greenwich)
|
2009
|
0.75
|
|
118
|
The geriatric paradox.
|
Am J Geriatr Cardiol
|
2008
|
0.75
|
|
119
|
Valvular heart disease at elderly age: new vistas.
|
Am J Geriatr Cardiol
|
2006
|
0.75
|
|
120
|
Anticoagulation at elderly age: the challenge to do better.
|
Am J Geriatr Cardiol
|
2003
|
0.75
|
|
121
|
Newer diagnostic strategies, application of evidence-based therapies: improving cardiovascular outcomes in an expanding elderly population.
|
Am J Geriatr Cardiol
|
2007
|
0.75
|
|
122
|
Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: the VALUE trial.
|
Blood Press
|
2008
|
0.75
|